Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #50 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Morepen Laboratories Limited (this stock) | 7,413 | 66.0 | 7.6% | 177.6% | 0.15% | 64 | 34 | 55 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 570 | 75 | 56 | ₹ |
| March 31, 2026 | 485 | 23 | 16 | ₹ |
| Dec. 31, 2025 | 484 | 35 | 28 | ₹ |
| Sept. 30, 2025 | 412 | 46 | 41 | ₹ |
| June 30, 2025 | 425 | 16 | 11 | ₹ |
| March 31, 2025 | 466 | 26 | 20 | ₹ |
| Dec. 31, 2024 | 453 | 35 | 27 | ₹ |
| Sept. 30, 2024 | 438 | 46 | 35 | ₹ |
| June 30, 2024 | 455 | 48 | 36 | ₹ |
| March 31, 2024 | 423 | 42 | 28 | ₹ |
| Dec. 31, 2023 | 445 | 44 | 32 | ₹ |
| Sept. 30, 2023 | 422 | 29 | 21 | ₹ |
| June 30, 2023 | 401 | 21 | 15 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 1,806 | 120 | 95 |
| March 31, 2025 | 1,812 | 155 | 118 |
| March 31, 2024 | 1,690 | 135 | 96 |
| March 31, 2023 | 1,418 | 56 | 39 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 33 | -123 | 97 | 86 | -53 |
| March 31, 2025 | 32 | -322 | 300 | 124 | -92 |
| March 31, 2024 | 73 | -83 | 5 | 71 | 2 |
| March 31, 2023 | -91 | -47 | 144 | 36 | -127 |
| March 31, 2022 | -58 | -32 | 64 | 45 | -103 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 1,936 | 1,247 | 1,137 | 61 | 134 | 1,164 | 490 | 31 | 381 | 272 |
| March 31, 2025 | 1,778 | 1,187 | 1,047 | 54 | 26 | 1,159 | 501 | 27 | 317 | 300 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
